FDA grants NDPS license to OCHRI

 Orange City Hospital & Research Institute has been recognized by Food and Drug Administration- Maharashtra State to process, store and dispense all essential narcotic drugs used for treatment purposes under the Narcotic Drugs and Psychotropic Substances Act, 1985 & Rule 2015 through form No. 3G. The Narcotic Drugs and Psychotropic Substances Act, 1985, commonly referred to as the NDPS Act, is an Act of Parliament of India that prohibits a person to produce/manufacture/cultivate, possess, sell, purchase, transport, store, and/or consume any narcotic drug or psychotropic substance.

It is added that many pain killers and Anaesthesia drugs come under preview of Essential Narcotic Drug Act. It is crucial that all hospitals which are having operation theatres and Critical Care units should get recognition under this Act; failing which serious actions can be contemplated by FDA against them. The 40 bedded OCHRI Critical Care Complex caters to varied complicated cases patients reaching from all corners of Central India for solace. Respecting the law, OCHRI accordingly approached FDA for granting license so as to prevent any inadvertent law break of any kind.

This recognition granted by Shri. A. T. Nikhade, Joint Commissioner and Licensing Authority FDA- Maharashtra Mumbai was conveyed by Dr. Rakesh Tirpude, Assistant Commissioner Food and Drugs Administration, Nagpur Division to OCHRI recently. Dr. Neeta Deshpande, MD has been nominated by OCHRI as Nodal Officer as per norms.

Dr. Anup Marar, Director- OCHRI has thanked FDA authorities for the confidence reposed on the expertise and integrity of Team OCHRI by granting this crucial NDPS license and assured that Dr. Neeta Deshpande- Nodal Officer assisted by Shri.Niraj Patil- Pharmacist will maintain and follow requisite norms to justify their trust on OCHRI.